No
preferential access to Themis' potential COVID-19
vaccine: CEO
Send a link to a friend
[May 28, 2020]
VIENNA (Reuters) - Nobody will get
preferential access to a potential COVID-19 drug developed by vaccine
maker Themis Bioscience, which is being bought by U.S. pharmaceuticals
firm Merck & Co Inc, the Austrian firm's chief executive said on
Thursday.
|
"Merck has already demonstrated in the past... that it makes
vaccines available to anybody who needs them," Erich Tauber told
Reuters on Thursday, adding a potential vaccine would be made
available globally.
"It is one of the reasons why we have decided to cooperate with
Merck."
![](http://archives.lincolndailynews.com/2020/May/28/images/ads/current/ldn_more4_121715.png)
Clinical tests for the Themis vaccine, which is based on a
genetically modified measles virus that delivers bits of the
SARS-CoV-2 virus into the human body to prevent COVID-19.
[to top of second column] |
![](http://archives.lincolndailynews.com/2020/May/28/images/ads/current/castlemanor_sda_FINANCIAL_2017.png)
It will start soon in France and Belgium, Tauber said, with plans to
then extend to other European countries and the United States
quickly.
(Reporting by Kirsti Knolle; editing by Jason Neely)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |